The CAR T‐cell therapy may be ineffective when the cancer cells change the quantity or the actual surface CD19 epitope expression through one or several genetic mechanisms such as splice variation, mutations, or lineage switching,21, 22, 23 thus allowing the cancer cells to escape recognition by the scFv of the CAR T cells. This evidence concerns the gene CD19 and cancer.